TherapeuticsMD, Inc. (NASDAQ:TXMD) Short Interest Down 43.7% in January

TherapeuticsMD, Inc. (NASDAQ:TXMD) was the target of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 12,000 shares, a decrease of 43.7% from the December 31st total of 21,300 shares. Approximately 0.1% of the company’s shares are sold short. Based on an average daily volume of 275,000 shares, the short-interest ratio is currently 0.0 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on TherapeuticsMD in a research report on Tuesday, January 14th. They issued a “hold” rating on the stock.

TherapeuticsMD Trading Down 2.3 %

Shares of NASDAQ:TXMD traded down $0.03 during trading on Wednesday, reaching $1.07. The stock had a trading volume of 11,577 shares, compared to its average volume of 945,915. TherapeuticsMD has a 52 week low of $0.70 and a 52 week high of $2.75. The firm’s fifty day moving average is $1.19 and its 200 day moving average is $1.50.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.05) earnings per share for the quarter. TherapeuticsMD had a negative return on equity of 14.08% and a negative net margin of 207.77%. The business had revenue of $0.55 million during the quarter.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.